Who
Jing L. Marantz
Director
Company insider
Files Form 4 as: Director, Arcturus Therapeutics Holdings; Chief Medical Officer, Scholar Rock Holding; Chief Business Officer, Krystal Biotech.
In numbers
- Trades disclosed
- 43
- Buys
- 0
- Sells
- 7
- Bought
- $0
- Sold
- $4.5M
- Companies
- 3
- Companies where not an officer
- 1
- First trade
- 4 Jan 2021
- Last trade
- 5 Jun 2026
- Last filed
- 15 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 5 Jun 2026filed 15 Jun 2026 | ARCT Arcturus Therapeutics Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 5 Jun 2026filed 15 Jun 2026 | ARCT Arcturus Therapeutics Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 17 Feb 2026filed 19 Feb 2026 | SRRK Scholar Rock HoldingBiotechnology | SEC FORM 4 Sold | $193K4,157 at $46.53 | filing |
| 17 Feb 2026filed 19 Feb 2026 | SRRK Scholar Rock HoldingBiotechnology | SEC FORM 4 Sold | $193K4,157 at $46.53 | filing |
| 9 Feb 2026filed 11 Feb 2026 | SRRK Scholar Rock HoldingBiotechnology | SEC FORM 4 Code A | —34,482 at $0.00 | filing |
| 9 Feb 2026filed 11 Feb 2026 | SRRK Scholar Rock HoldingBiotechnology | SEC FORM 4 Code A | —34,482 at $0.00 | filing |
| 16 Jan 2026filed 21 Jan 2026 | SRRK Scholar Rock HoldingBiotechnology | SEC FORM 4 Sold | $258K5,798 at $44.48 | filing |
| 16 Jan 2026filed 21 Jan 2026 | SRRK Scholar Rock HoldingBiotechnology | SEC FORM 4 Sold | $258K5,798 at $44.48 | filing |
| 9 Jun 2025filed 11 Jun 2025 | ARCT Arcturus Therapeutics Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 10 Mar 2025filed 12 Mar 2025 | SRRK Scholar Rock Holdingoption or derivative · Biotechnology | SEC FORM 4 Code A | —45,715 at $0.00 | filing |
| 10 Mar 2025filed 12 Mar 2025 | SRRK Scholar Rock HoldingBiotechnology | SEC FORM 4 Code A | —34,285 at $0.00 | filing |
| 16 Jan 2025filed 21 Jan 2025 | SRRK Scholar Rock HoldingBiotechnology | SEC FORM 4 Sold | $250K5,655 at $44.20 | filing |
| 25 Nov 2024filed 26 Nov 2024 | SRRK Scholar Rock Holdingoption or derivative · Biotechnology | SEC FORM 4 Code M | —6,375 at $0.00 | filing |
| 25 Nov 2024filed 26 Nov 2024 | SRRK Scholar Rock HoldingBiotechnology | SEC FORM 4 Code M | $55K6,375 at $8.59 | filing |
| 25 Nov 2024filed 26 Nov 2024 | SRRK Scholar Rock HoldingBiotechnology | SEC FORM 4 Sold | $38K1,000 at $38.04 | filing |
| 25 Nov 2024filed 26 Nov 2024 | SRRK Scholar Rock HoldingBiotechnology | SEC FORM 4 Sold | $82K2,100 at $39.25 | filing |
| 25 Nov 2024filed 26 Nov 2024 | SRRK Scholar Rock HoldingBiotechnology | SEC FORM 4 Sold | $123K3,075 at $39.93 | filing |
| 25 Nov 2024filed 26 Nov 2024 | SRRK Scholar Rock HoldingBiotechnology | SEC FORM 4 Sold | $8,144200 at $40.72 | filing |
| 22 Nov 2024filed 26 Nov 2024 | SRRK Scholar Rock Holdingoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,145 at $0.00 | filing |
| 22 Nov 2024filed 26 Nov 2024 | SRRK Scholar Rock HoldingBiotechnology | SEC FORM 4 Code M | $18K2,145 at $8.59 | filing |
News
Intellia Therapeutics Appoints Jing L. Marantz, M.D., Ph.D., as Chief Medical Officermanilatimes.net · 13 Oct 2026Scholar Rock Resubmits Marketing Authorisation Application For ApitegromabSRRK · rttnews.com · 8 Oct 2026
1 headline in the last 90 days name Jing L. Marantz; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.